Explore Our Technology
KREX® Protein-folding
Technology
Accelerating biomarker discovery and autoantibody profiling by expression and purification of full-length, correctly folded proteins.
Technology
Innovative technology is at the core of Sengenics’ ability to identify and develop clinically relevant autoantibody biomarkers. Explore our proprietary technologies and learn how autoantibodies may hold the key to significant, new advances in precision medicine.
Accelerating biomarker discovery and autoantibody profiling by expression and purification of full-length, correctly folded proteins.
Learn how the unique characteristics of autoantibodies make them such powerful and predictive biomarkers of disease and therapeutic response.
Learn why a specialized approach to bioinformatics is required for discovering predictive autoantibody biomarker signatures.
Sengenics, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline.
© 2024 Sengenics Corporation LLC. All rights reserved. Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D
Terms & Conditions | Terms of Use | Privacy Statement | Cookie Policy | Code of Conduct | Whistleblowing Policy | Sitemap
Design and development by RainCastle Communications.
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields
"*" indicates required fields